Manufacturing

Articles

A Q&A with James Ingebrand, Vice President and General Manager of 3M Drug Delivery Systems Division, on recent industry trends.

Q&A with James Ingebrand, 3M Drug Delivery Systems Division

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.

Gauging Biopharm Outsourcing

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

MedImmune, the global biologics arm of AstraZeneca, announced that it is restructuring its infectious disease and vaccines R&D and operations. This will result in the closure of MedImmune's sites in Mountain View and Santa Clara, California.

AstraZeneca Restructures Vaccines R&D and Operations

Novartis, GlaxoSmithKline, and Lonza are among those participating in newly formed consortiums for developing and producing medical countermeasures.

US Government Awards $400 Million in Contracts for Vaccine Manufacturing

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Dr. Reddy's Laboratories and Merck Serono, a division of Merck KGaA, have partnered to codevelop a portfolio of biosimilar compounds in oncology.

Dr. Reddy's and Merck Serono Team Up on Biosimilars

BIO is calling for a more patient-centric approach to user-fee reauthorization.

Back-to-Basics with PDUFA V

Angie Drakulich was editorial director of Pharmaceutical Technology.

FDA issued a final rule on sterility testing on May 3, 2012, which amends the requirements for most licensed biological products and aims to provide manufacturers with the flexibility, as appropriate, to keep pace with technological and scientific advances. Many steps are changed or eliminated.

FDA Issues Final Rule on Sterility Testing of Biologics

The author discusses potential opportunities to improve the patient experience through formulation and delivery device technologies.

Optimizing Drug Delivery for Modern Biologics

Amy Ritter was Scientific Editor, BioPharm International.

Readers share their views on bioprocessing challenges, equipment use, and outsourcing trends in our annual bioprocessing equipment and processing survey.

Bioprocessing Trends: Annual Survey Results

Collaboration can begin with a conversation.

Manufacturing, Biologic Drugs